Biomarkers /
PIK3CA
Overview
PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) is a gene that encodes the protein phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, a subunit of the PI3K protein. Phosphatidyl 3-kinases (PI3K) are a family of lipid kinases involved in many cellular processes, including cell growth, proliferation, differentiation, motility, and survival. Mutant PIK3CA has been implicated in the pathogenesis of several cancers, including colon cancer, glioma, gastric cancer, breast cancer, endometrial cancer, and lung cancer (COSMIC; PMID: 15016963).
PIK3CA is altered in 12.66% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, lung adenocarcinoma, and breast invasive lobular carcinoma having the greatest prevalence of alterations [3].
The most common alterations in PIK3CA are PIK3CA Mutation (12.16%), PIK3CA Codon 1047 Missense (3.28%), PIK3CA Codon 545 Missense (2.88%), PIK3CA H1047R (2.93%), and PIK3CA E545K (2.61%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of PIK3CA in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.